A patient with transthyretin amyloidosis (ATTR) who received the investigational gene therapy nexiguran ziclumeran (nex-z) in ...

The Cambridge-based biotech company is studying the use of Crispr, the Nobel Prize-winning gene-editing technology, to treat ...

New Delhi, Nov 7 (PTI) Citing several case studies from India, the World Economic Forum on Friday said seven emerging deep technologies, including generative AI, robotics and satellite-enabled remote ...

Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...

The extinction of Neanderthals, our closest extinct human relatives, has long been a subject of intrigue and speculation. A ...

The Hippo signaling pathway that helps control tissue size in animals and malfunctions in cancers already existed before ...

Learn more about whether BioMarin Pharmaceutical Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Intellia had already paused dosing in trials of nex-z in transthyretin amyloidosis after the patient was hospitalized due to a serious adverse event.

NEW ORLEANS -- Innovations in lipid lowering get a major chance to shine, and potentially move the needle in cardiometabolic ...

Scientists at Georgia State University have used CRISPR gene editing to restore an ancient enzyme humans lost millions of years ago potentially reversing the buildup of uric acid that causes gout.

How do regulators address concerns in the court of evidentiary decision making -- and of public opinion -- surrounding ...

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred.